About
HeraMED is a technology start-up company developing connected pregnancy monitoring solutions for home use. HeraMEDs hardware solutions and software applications are focused on fetal well-being and parental assurance. The companys HeraBEAT is a medically accurate and scientifically optimized smartphone-based fetal heartbeat monitor for home use. HeraBEAT allows expectant mothers to monitor the fetal heartbeat anytime, anywhere and enables the seamless sharing of fetal vital sign data with medical professionals. HeraBEAT integrates technology and professional accuracy with a simple and straightforward user interface and a distinctive design, resulting in a safe, reliable, and affordable solution. HeraBEAT is BSI certified with the CE mark for medical devices. It received 510(k) clearance from the FDA in November 2019. The companys HeraCARE is a digital platform enabling a new model of care for women throughout pregnancy. HeraMEDs future products include the EchoBEAT line of home-based pregnancy monitoring devices and ORION, an AI-powered pregnancy monitoring system. Developed in cooperation with the Mayo Clinic, Orion is trained to detect precursors that can indicate possible pregnancy complications before they become a problem.
Funding history · 9 rounds · $23.8M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did HeraMED receive FDA clearance for its HeraBEAT device?
- HeraMED received 510(k) clearance from the FDA for its HeraBEAT device in November 2019.
- What is HeraMED's current public status and on which exchange is it listed?
- HeraMED is currently a public company, listed on the ASX (Australian Securities Exchange) since December 2018 under the ticker HMD. It also had an IPO in June 2020.
- Which major medical institution is collaborating with HeraMED on its ORION AI-powered pregnancy monitoring system?
- HeraMED is developing its ORION AI-powered pregnancy monitoring system in cooperation with the Mayo Clinic. The Mayo Clinic also approved a clinical study of HeraMED's HeraBEAT device in December 2020 and invested in HeraMED in July 2020.
- What was HeraMED's financial performance in the first half of 2025?
- In the first half of 2025, HeraMED reported an AU$0.003 loss per share, which is an improvement compared to an AU$0.009 loss in the first half of 2024.
- Which Israeli hospital initiated a pilot program for HeraMED's pregnancy technology in February 2021?
- Israel's largest hospital initiated a pilot program for HeraMED's pregnancy technology in February 2021.
- What was HeraMED's total funding raised in USD?
- HeraMED has raised a total of $23,763,500 USD. For a full financing history, users can refer to startupim.
- When was HeraMED founded and where is its headquarters located?
- HeraMED was founded in October 2011 and its headquarters is located in Netanya, Israel.
- What is HeraMED's HeraCARE platform designed for?
- HeraMED's HeraCARE is a digital platform designed to enable a new model of care for women throughout pregnancy.
- What was HeraMED's market capitalization as of January 2026?
- As of January 1, 2026, HeraMED's market capitalization was $25,698,051 USD.